Trials
Search / Trial NCT05653986

An Observational Study to Assess Change in Disease Activity When Ubrogepant Tablets Are Combined With Atogepant Tablets to Treat Migraine in Adult Participants

Launched by ABBVIE · Dec 14, 2022

Apply for Trial

Trial Information

Current as of February 05, 2025

Completed

Keywords

Migraine Ubrogepant Ubrelvy Atogepant Qulipta

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • • Reports meeting migraine diagnostic criteria consistent with International Classification of Headache Disorders (ICHD) (i.e., they report symptoms accompanying their headaches that meet migraine criteria22 at screening).
  • • Currently using ubrogepant for acute treatment of migraine.
  • • Experienced at least 3 migraine attacks in the last 30 days.
  • • Currently taking atogepant for preventive treatment of migraine and has been taking atogepant, at the same dose, for at least 30 days.
  • Exclusion Criteria:
  • • Report currently taking Rimegepant (Nurtec®) for migraine treatment (acute or preventive).
  • * Report currently taking any of the anti-CGRP mAbs for preventive treatment of migraine:
  • • Erenumab (Aimovig®)
  • • Galcanezumab (Emgality®)
  • • Fremanezumab (Ajovy®)
  • • Eptinezumab (Vyepti®)

Trial Officials

ABBVIE INC.

Study Director

AbbVie

About Abbvie

AbbVie is a global biopharmaceutical company dedicated to developing innovative therapies that address complex health challenges. Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie focuses on key therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is committed to advancing scientific research and delivering groundbreaking treatments that enhance patient outcomes and quality of life. With a robust pipeline and a strong emphasis on collaboration, AbbVie strives to transform the future of medicine through its commitment to clinical excellence and patient-centered approaches.

Locations

Bronx, New York, United States

Bronx, New York, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials